TG Therapeutics Ukoniq’s Future In Doubt Amidst Scrutiny Of P13K Inhibitor Accelerated Approvals

Advisory committee review of combo with ublituximab may provide forum to discuss the Phase III data showing increased risk of death that prompted US FDA safety alert.

GREEN BLURRY BUBBLES
The risk profile of the leukemia and lymphoma therapies are blurry after FDA's drug safety communication. • Source: Alamy

TG Therapeutics, Inc.’s Ukoniq (umbralisib) is the latest drug to stumble over the safety issues that have long plagued the phosphatidylinositol 3-kinase (PI3K) inhibitor class. The small group of leukemia and lymphoma therapies are getting a new level of regulatory attention as the US FDA builds out from its 2021 crackdown on “dangling” and “delinquent” accelerated approvals in oncology.

The FDA is “investigating a possible increased risk of death” with Ukoniq, according to a drug safety communication issued on...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Review Pathways

More from Pathways & Standards